

**INFORMATION DISCLOSURE  
STATEMENT****BY APPLICANT**

Docket: 4239-60808

App: \_\_\_\_\_

Applicant: Shearer et al.

Filed: Herewith

Art Unit: \_\_\_\_\_

**U.S. PATENT DOCUMENTS**

Init.*		Number	Date	Name	Class	Sub	Filed
MB		4,728,614	3/1/1988	Lau	_____	_____	
↓		5,095,095	3/10/1992	Fontana	_____	_____	
↓		5,468,481	11/21/1995	Sharma et al.	_____	_____	
MB		5,871,728	2/16/1999	Thomson et al.	_____	_____	

**FOREIGN PATENT DOCUMENTS**

		Number	Date	Country	Class	Sub	
MB		0 155 433	25.09.85	EPC	_____	_____	
↓		0 159 289	23.10.85	EPC	_____	_____	
MB		WO 96/29394	26.09.96	PCT	_____	_____	

**OTHER DOCUMENTS**

		ATCC No.: CRL-1690.	
		ATCC No.: CRL-2020.	
		ATCC No.: CRL-2365.	

EXAMINER:

DATE

3/6/03

\*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.

<b>INFORMATION DISCLOSURE STATEMENT</b>  <b>BY APPLICANT</b>	Docket: 4239-60808	App: _____
	Applicant: Shearer et al.	
	Filed: Herewith	Art Unit: _____

### OTHER DOCUMENTS


		ATCC No.: CRL-2366. ✓
		ATCC No.: HTB-16.
		ATCC No.: CRL-1620. ✓
		"TGF-beta 2 Antisense Gene Therapy for Glioblastoma," <i>Cytokine Bulletin</i> , Spring 1997.
		Bluestone, "Transplantation Tolerance: The Next Frontier," <i>New Developments in Transplantation Medicine, Vol. 1</i> , Spring 1994.
MB		Elliott et al., "Suppression of High Affinity IL-2 Receptors on Mitogen Activated Lymphocytes by Glioma-Derived Suppressor Factor," <i>J. Neuro-Oncol.</i> 14:1-7 (1992).
		Fontana et al., "Glioblastoma Cells Release Interleukin 1 and Factors Inhibiting Interleukin 2-Mediated Effects," <i>J. Immunol.</i> 132:1837-1844 (1984).
		Mapstone et al., "Expression of Platelet-Derived Growth Factors, Transforming Growth Factors, and the <i>ros</i> Gene in a Variety of Primary Human Brain Tumors," <i>Neurosurg.</i> 28:216-222 (1991).
MB		Marquardt et al., "Complete Amino Acid Sequence of Human Transforming Growth Factor Type Beta 2," <i>J. Biol. Chem.</i> 262:12127-12131 (1987).

EXAMINER:

DATE

3/6/03

\*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.

<b>INFORMATION DISCLOSURE STATEMENT</b>  <b>BY APPLICANT</b>			Docket: 4239-60808	App: _____
			Applicant: Shearer et al.	
			Filed: Herewith	Art Unit: _____
<b>OTHER DOCUMENTS</b>				
MB			Morford et al., "Apoptotic Elimination of Peripheral T Lymphocytes in Patients with Primary Intracranial Tumors, <i>J. Neurosurg.</i> 91:935-946 (1999).	
			Pisetsky, "11. Systemic Lupus Erythematosus. A. Epidemiology, Pathology, and Pathogenesis," in <i>Primer on Rheumatic Diseases</i> , pp. 100-105 (_____).	
MB			Schwyzer et al., "Partial Purification and Biochemical Characterization of a T Cell Suppressor Factor Produced by Human Glioblastoma Cells," <i>J. Immunol.</i> 134:1003-1009 (1985).	
↓ MB			Zou et al., "Human Glioma-Induced Immunosuppression Involves Soluble Factor(s) that Alters Monocyte Cytokine Profile and Surface Markers," <i>J. Immunol.</i> 162:4882-4892 (1999).	
EXAMINER: 			DATE 3/6/03	
*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.				